Trupanion Inc

Trupanion Inc(TRUP)股票分析

$29.210

-0.549 (-1.88%)收盘时

Loading chart…
最高
29.690
开盘
29.680
成交量加权均价
29.15
成交量
567.11K
市值
1.25B
最低
28.545
成交额
16.53M
企业价值/息税折旧摊销前利润(TTM)
28.93

Trupanion, Inc. is a medical insurance provider for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe. The Company operates in two segments, namely, Subscription Business and Other Business. The Subscription Business segment is based on subscription payments related to the Company’s direct-to-consumer products. The Other business segment is focuses on other product offerings, primarily involving the underwriting of policies on behalf of third parties with whom the Company maintains business-to-business relationships. It offers Trupanion, software that is designed to communicate directly with veterinary hospital's practice management software. It provides Powered by Trupanion pet insurance product offerings marketed by third parties and marketed under the brand names Furkin and PHI Direct in Canada, and a Trupanion branded product in Germany and Switzerland.

AI 分析 of Trupanion Inc (TRUP)

持有

Trupanion Inc is currently priced at $29.32, which is near the analyst price target range of $30 to $32. The stock has shown a 5-day increase of 4.27% and a significant year-over-year revenue growth of 11% in Q2 2026, indicating potential for recovery. However, the RSI is at 71.298, suggesting the stock may be overbought, and the forward P/E ratio is extremely high at 1428.57, indicating potential overvaluation. The main risk is the declining trend in the pet insurance market, as highlighted by Piper Sandler's downgrade due to a contraction in U.S. puppy vet visits, which could impact future growth.

分析师评级(6)

上行空间 +86.24%
买入
6 买入
0 持有
0 卖出
当前: 29.21
最低
42.00
平均
54.40
最高
63.00

Cantor Fitzgerald

2026-10-07

目标价

$30

中性

Piper Sandler

2026-08-26

目标价

$32

中性

Stifel

2026-08-20

目标价

$29

持有

BofA

2026-07-15

目标价

$42

买入

BofA

2026-05-01

目标价

$52

买入

估值指标

Trupanion Inc(TRUP)当前预期市盈率为 1428.57,5 年平均预期市盈率为 120.13。

预期市盈率

合理
5 年均值 P/E
120.13
当前P/E
1428.57
高估
1730.73
低估
-1490.47

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
6.46
当前EV/EBITDA
28.93
高估
490.80
低估
-477.87

预期市销率

合理
5 年均值 P/S
1.66
当前P/S
0.75
高估
2.90
低估
0.42

Alphio AI 对 TRUP 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%TRUP

$54.58

情景价格

基

基准

基准 · 50%TRUP

$45.54

情景价格

悲

悲观

悲观 · 25%TRUP

$34.42

情景价格

持有 TRUP 的大户

C

Check Capital Management Inc

+ 持有TRUP

-2.92%

3个月收益率

事件时间线

2026-08-05 (ET)

17:30:00

Company Authorizes Share Repurchase Program Up to $100M

17:30:00

Trupanion Q2 Revenue $392.93M Beats Expectations

2026-04-30 (ET)

16:40:00

Trupanion Reports Q1 Revenue of $384M

2026-03-10 (ET)

09:10:00

Trupanion Partners with HABRI to Strengthen Human-Animal Bond

2026-02-12 (ET)

16:30:00

Trupanion Q4 Revenue $376.9M Exceeds Expectations

资讯

TRUP 常见问题 —— 由 Alphio AI 解答

Trupanion, Inc. is a medical insurance provider for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe. The Company operates in two segments, namely, Subscription Business and Other Business. The Subscription Business segment is based on subscription payments related to the Company’s direct-to-consumer products. The Other business segment is focuses on other product offerings, primarily involving the underwriting of policies on behalf of third parties with whom the Company maintains business-to-business relationships. It offers Trupanion, software that is designed to communicate directly with veterinary hospital's practice management software. It provides Powered by Trupanion pet insurance product offerings marketed by third parties and marketed under the brand names Furkin and PHI Direct in Canada, and a Trupanion branded product in Germany and Switzerland. It operates in the Financials sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Trupanion Inc is currently priced at $29.32, which is near the analyst price target range of $30 to $32. The stock has shown a 5-day increase of 4.27% and a significant year-over-year revenue growth of 11% in Q2 2026, indicating potential for recovery. However, the RSI is at 71.298, suggesting the stock may be overbought, and the forward P/E ratio is extremely high at 1428.57, indicating potential overvaluation. The main risk is the declining trend in the pet insurance market, as highlighted by Piper Sandler's downgrade due to a contraction in U.S. puppy vet visits, which could impact future growth.

6 analysts cover TRUP: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 54.40.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易